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Mutations in a 69-bp region of the rpoB gene of Mycobacterium tuberculosis are associated with rifampin
resistance (Rifr). These have been detected with mycobacterial DNA extracted from bacterial suspensions or
respiratory specimens that were acid-fast smear positive. We experimented with a strategy for the rapid
detection of Rifr in cerebrospinal fluid (CSF) samples. The strategy involves the amplification of the 69-bp
region of rpoB by means of PCR and the identification of nucleotide mutations by single-strand conformation
polymorphism (SSCP) analysis of the amplification products. Sixty-five CSF specimens collected from 29
patients (19 patients were coinfected with human immunodeficiency virus) with culture or autopsy-confirmed
(22 patients) or highly probable (7 patients) tuberculosis of the central nervous system (CNS-TB) were
processed. Amplified products suitable for evaluation by SSCP analysis were obtained from 37 CSF specimens
from 25 subjects (86.2%). PCR-SSCP of CSF correctly identified the rifampin susceptibility phenotype of
isolates from all 17 patients for whom the results of susceptibility tests carried out with strains cultured from
CSF or respiratory samples were available. Moreover, this assay revealed the rifampin susceptibility genotype
of isolates from the eight patients (three patients with culture-confirmed CNS-TB and five patients in whom
CNS-TB was highly probable) for whom no susceptibility test results were available; the PCR-SSCP data
obtained for these patients were concordant with the outcome after a standard antituberculosis treatment. The
evolution of a mutation in the rpoB gene was documented in a patient during the course of treatment.
PCR-SSCP analysis of CSF seems to be an efficacious method of predicting Rifr and would reduce the time
required for susceptibility testing from approximately 4 to 8 weeks to a few days.
Tuberculosis is still an important cause of morbidity and
mortality throughout the world. The steady decline in the in-
cidence of tuberculosis, both in the Third World and in indus-
trialized countries, which followed the introduction of ef-
fective chemotherapy, was reversed in the mid-1980s mainly
due to epidemic human immunodeficiency virus (HIV) in-
fection (6, 14). Tuberculosis of the central nervous system
(CNS-TB) is a severe condition which, if left untreated,
leads to a fatal outcome within 4 to 8 weeks of the onset of
symptoms. An early and accurate diagnosis and administra-
tion of an effective chemotherapy could improve the out-
come and reduce the neurological sequelae (13, 17). The
increased occurrence of tuberculosis is paralleled by the
emergence of multidrug-resistant isolates of Mycobacterium
tuberculosis, which are at least resistant to rifampin and
isoniazid (5). The rapid availability of information concern-
ing drug susceptibility patterns is important not only be-
cause it makes it possible to select adequate multidrug reg-
imens but also because it contributes to minimizing the
spread of drug-resistant strains. Since isolation, identifica-
tion, and susceptibility testing by conventional procedures
can take 4 to 8 weeks, it would be a great advantage to be
able to obtain accurate results in a shorter time.
Rifampin is an essential component of therapeutic regimens
and is most frequently used in combination with isoniazid,
pyrazinamide, and ethambuthol. Rifampin resistance (Rifr) in
mycobacteria is most often due to point mutations and small
insertions and deletions located in a 69-bp region of the rpoB
gene encoding the b-subunit of the RNA polymerase (4, 7, 10,
12, 19, 20, 22, 23), a mechanism that was first documented in
Escherichia coli and Mycobacterium leprae (9, 11). DNA-based
diagnostic assays, such as single-strand conformation polymor-
phism (SSCP), heteroduplex formation, and automated DNA
sequence analyses have been used for the detection of muta-
tions in the PCR amplification products of the rpoB gene (4, 7,
10, 12, 19, 20, 22, 23), but the detection of Rifr by these
methods has largely been limited to bacterial suspensions of
clinical isolates of M. tuberculosis or clinical specimens with a
high burden of bacilli, such as smear-positive respiratory sam-
ples.
We present here the results of our experience with a PCR
assay coupled with a manual SSCP analysis for the evaluation
of Rifr directly from the cerebrospinal fluid (CSF) of patients
with confirmed or highly probable CNS-TB. The PCR-SSCP
analysis data obtained by processing both CSF samples and M.
tuberculosis strains isolated from the same patients were com-
pared with the rifampin susceptibility phenotype. Sequence
analysis of PCR products from bacterial suspensions was car-
ried out in order to characterize the mutations. The sensitivity
of PCR amplification of the rpoB sequence was compared with
that of another homemade nested PCR protocol amplifying
IS6110. The clinical strains were also characterized by exam-
ining their IS6110 restriction fragment length polymorphism
(RFLP) patterns in order to determine the spread of a limited
number of clones.
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MATERIALS AND METHODS
Clinical samples. We studied a total of 65 CSF samples obtained by means of
diagnostic lumbar punctures from 29 patients (19 patients were HIV seroposi-
tive) admitted to various hospitals in northern Italy over a period of 6 years (1992
to 1997). Only a single CSF sample was available from 11 patients, whereas
additional specimens were also collected from the remaining 18 patients during
the administration of antituberculosis compounds (see Table 1). The clinical
diagnoses of CNS-TB were confirmed by means of M. tuberculosis-positive CSF
cultures for 19 patients and at autopsy for 3 patients; for the remaining 7
patients, the diagnosis of CNS-TB was considered highly probable because the
suggestive clinical picture was accompanied by at least three of the following
supporting tests: (i) compatible abnormal CSF findings, including increased
leukocyte counts (mainly lymphocytes), hypoglycorrhachia, protein concentra-
tion of more than 100 mg/dl, and sterile routine bacterial and fungal cultures; (ii)
computed tomography findings suggesting CNS-TB (basal exudate, hydroceph-
alus, and intracranial tuberculomas); (iii) evidence of tuberculosis outside the
CNS; and (iv) clinical response to antituberculosis therapy (Table 1).
An aliquot of each CSF sample underwent microscopic examination for acid-
fast bacilli, culture for M. tuberculosis, and DNA amplification by two PCR
protocols. The first PCR protocol amplified a fragment of IS6110, and the second
produced an amplification product of the region identified as the Rifr locus
contained in the rpoB gene, which was used for the subsequent detection of
mutations by SSCP analysis. CSF aliquots of 1 to 2 ml were concentrated by
centrifugation (3,000 3 g for 10 min) for conventional bacteriological examina-
tion; the sediments were used to prepare smears for direct examination by means
of auramine-rhodamine staining and were cultured by inoculation on Lowen-
stein-Jensen medium (samples processed before 1993) or BACTEC 12B medium
(Becton Dickinson Diagnostic Instruments, Sparks, Md.) for radiometric detec-
tion of mycobacterial growth (samples processed from 1993 onward). The cul-
tures on solid media were aerobically incubated in an atmosphere with 5% CO2
at 37°C. All cultures were observed for 12 weeks before they were discarded.
Routine biochemical methods and the Accuprobe culture confirmation kits
(Gen-Probe, San Diego, Calif.) were used to identify the isolates. The suscepti-
bility to rifampin was determined by the BACTEC radiometric method. The
critical concentration of rifampin in BACTEC 12B vials was 2 mg/ml. The MICs
for resistant strains were measured by the dilution method on Middlebrook 7H11
agar medium (8).
Mycobacterial strains. Seventeen M. tuberculosis strains cultured from pa-
tients with CNS-TB were used for PCR-SSCP analysis and for direct DNA
sequencing. Strains were classified on the basis of IS6110 RFLP pattern subtypes,
according to internationally standardized guidelines (21). The rifampin-sensitive
isolate M. tuberculosis H37rv (ATCC 27294) and seven rifampin-resistant M.
tuberculosis clinical isolates with different mutations located in the Rifr region
were used as controls.
Sample preparation and PCR amplification. Bacterial suspensions, containing
approximately 105 acid-fast bacilli in 250 ml of sterile deionized H2O and 500 ml
of each CSF specimen underwent DNA extraction and purification by the chao-
trope-silica method described by Boom et al. (3). The DNA (10 ml) extracted
from the bacterial suspensions was used for amplification of the Rifr region
(GenBank accession no. L05910) with primers TR9 (59-TCGCCGCGATC
AAGGAGT) and TR8 (59-TGCACGTCGCGGACCTCCA) by the protocol
described by Telenti et al. (20). The DNA (10 ml) extracted from the CSF
specimens was used for time-release PCR of the Rifr region with primers TR8
and TR9. The PCR mixture (100 ml) contained 50 mM KCl, 10 mM Tris-HCl
(pH 8.4), 1.5 mM MgCl2, 200 mM (each) dATP, dGTP, and dTTP, 100 mM
dCTP, 0.5 ml (5 mCi) of [a-32P]dCTP, and the primers (0.5 mM each); 2.5 U of
AmpliTaq Gold DNA polymerase (Perkin-Elmer Cetus, Emeryville, Calif.) was
added to each tube. The reaction was subjected to a 2-min pre-PCR heating step
at 95°C, followed by 20 PCR cycles of 1 min each at 95, 63, and 72°C, 30 PCR
cycles of 30 s at 96°C and 1 min each at 60 and 72°C, and a final 15-min extension
at 72°C in a Perkin-Elmer 480 thermal cycler. In order to analyze the PCR
product, 10 ml of the reaction solution was electrophoresed on a 1.8% agarose
gel containing 0.5 mg of ethidium bromide per ml. The presence of a 157-bp band
indicated a successful amplification. To exclude cross-contamination, a negative
control containing all the ingredients of the PCR mixture except the DNA
template was included for every two samples. Precautions to avoid false-positive
results were taken in every assay, as described previously (16).
Each CSF sample was also subjected to a nested PCR protocol for the final
amplification of a 123-bp product contained in IS6110, as described previously
(18).
The sensitivities of the two PCR protocols were determined by testing serial
twofold dilutions of an M. tuberculosis clinical strain as described by Kolk et al.
(15). The number of CFU per milliliter was estimated by means of routine
plating and colony counting by using triplicate Middlebrook 7H10 agar plates.
Simple heating to 95°C for 15 min was used to release DNA from bacterial cells
prior to amplification.
SSCP analysis. SSCP analysis was performed by mixing 25 ml of the PCR
product with 100 ml of SSCP dilution solution (10 mM EDTA, 0.1% sodium
dodecyl sulfate). The diluted product (10 ml) was mixed with 10 ml of gel loading
buffer (95% formamide, 0.05% bromophenol blue, 0.05% xylene cyanol, 20 mM
EDTA), and the mixture was heated for 10 min at 98°C, cooled on ice for 10 min,
and loaded onto a nondenaturing sequencing format 0.53 MDE gel composed
of 10 ml of MDE (Hydrolink; AT Biochem Inc., Malvern, Pa.), 4.8 ml of 53 TBE
buffer (0.45 M Tris-borate, 10 mM EDTA), and 25.2 ml of H2O polymerized with
40 ml of 25% ammonium persulfate and 50 ml of N,N,N9,N9-tetramethylethyl-
enediamine (TEMED; Bio-Rad, Richmond, Calif.). Electrophoresis was per-
formed at room temperature overnight at constant power (6 W for a gel of 55 by
20 by 0.04 cm). The gels were dried for 1 h at 80°C and were exposed overnight
for autoradiography.
DNA sequencing. Purified M. tuberculosis DNA from the clinical isolates and
reference strain was used to produce a 350-bp fragment of rpoB by using the
primers and PCR conditions described by Kapur et al. (12). The unincorporated
nucleotides and primers were separated from the amplified DNA using the
QIAquick PCR purification kit (Qiagen, Hilden, Germany). Sequencing was
carried out with an ABI 373 automated sequencer by using the PRISM dye
terminator cycle sequencing kit (Perkin-Elmer) according to the manufacturer’s
instructions. Both strands were sequenced. The data were assembled and edited
by using the Sequencer, version 3.0, analysis program (Gene Codes Corpora-
tion).
RESULTS
Sensitivities of PCR protocols. The detection limits of the
PCR for the rpoB gene and IS6110 of M. tuberculosis were 100
and 50 CFU/ml of the bacterial suspensions, respectively.
SSCP analysis. Figure 1 shows the SSCP patterns obtained by
processing the rifampin-sensitive strain M. tuberculosis H37rv
(ATCC 27294) and seven rifampin-resistant M. tuberculosis
clinical isolates with different mutations located in the Rifr
region that were used as controls.
Table 1 summarizes the results obtained by processing 65
CSF samples from 29 patients suffering from CSN-TB by using
the two PCR protocols, SSCP analysis of the amplified prod-
ucts of rpoB, and testing of the susceptibilities of the clinical
isolates to rifampin. A positive result was obtained for at least
one CSF sample from each patient with CNS-TB by the IS6110
PCR. Amplified products suitable for subsequent SSCP anal-
ysis were obtained from 37 CSF samples drawn from 25 of the
29 patients (86.2%) by the rpoB PCR. SSCP analysis showed
single DNA strands with electrophoretic mobilities that were
identical to that of a rifampin-sensitive wild-type strain (M.
tuberculosis H37rv [ATCC 27294]) for rpoB PCR products
from 19 samples collected from 17 patients with confirmed or
highly probable cases of CNS-TB, respectively (Table 1).
Twelve M. tuberculosis isolates were cultured from the CSF
FIG. 1. PCR-SSCP patterns obtained by processing rifampin-resistant M.
tuberculosis clinical isolates (samples [lanes] 1 to 7) and a rifampin-sensitive M.
tuberculosis reference strain (ATCC 27294) (lanes S). The rifampin-resistant
strains contained mutations in the rpoB gene located in codon 516, reading GTC
instead of GAC (Val3Asp) (sample 1); codon 526, reading AAC, CTC, GAC,
or TAC instead of CAC (His3Asn, Leu, Asp, or Tyr) (samples 2 to 5); codon
531, reading TTG instead of TCG (Ser3Leu) (sample 6); and codon 533,
reading CCG instead of CTG (Leu3Pro) (sample 7). All of these kinds of single
point substitutions were reported previously (12, 20). The finding of a three-band
SSCP pattern may reflect the presence of two possible conformations for one of
the DNA strands or a reannealing band. The codon numbers correspond to E.
coli RNA polymerase amino acid positions (11).
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specimens from these patients. Testing of susceptibility to ri-
fampin was carried out for nine of these strains and revealed a
sensitive phenotype. SSCP analysis showed an electrophoretic
mobility that was clearly different from that of the reference
strain for the rpoB PCR products obtained from 18 samples
drawn from nine patients with confirmed or highly probable
CNS-TB (Table 1). Among these patients three different SSCP
patterns were identified (Fig. 2). Eight M. tuberculosis strains
were cultured from the CSF samples or respiratory specimens
collected from these patients. All of these strains had pheno-
types of rifampin resistance, and the MICs for these strains
were $128 mg/liter. From patient 29 (Table 1; Fig. 2), we
processed a total of seven CSF samples collected over a 2-year
period. This patient had severe meningoencephalitis in 1994,
with the partial resolution of the symptoms and the neurora-
diological picture after 6 months of antituberculosis therapy;
then the patient worsened again and the therapy was modified.
SSCP analysis showed a change from a wild-type to an abnor-
mal pattern from the baseline to three subsequent CSF sam-
ples collected during the two episodes. The CSF samples col-
lected from this patient were negative upon culture and
microscopic examination.
The SSCP patterns obtained by processing the amplified
products obtained from suspensions of 17 M. tuberculosis iso-
lates and from CSF specimens collected from the same pa-
tients were also compared; no difference in the SSCP patterns
was observed.
Direct DNA sequencing and RFLP analysis. Seven different
kinds of point mutation were revealed in the rifampin-resistant
M. tuberculosis clinical strains that we used as controls. For
TABLE 1. SSCP analysis of CSF samples, patient data, results obtained by two PCR protocols, patterns by PCR-SSCP and susceptibilities of
clinical isolates to rifampin
Infection status and
patient no. Age (yr) Sex
a
No. of CSF samples
Pattern by
PCR-SSCP
analysis of CSFb
Rifampin
phenotypeTotal
Positive by
IS6110
PCR
Positive by
rpoB PCR
(evaluable
by SSCP)
Confirmed to have CNS-TB by CSF-positive culturec
1 32 Md 5 3 1 Wild type Sensitive
2 27 Fd 3 2 1 Wild type Sensitive
3 72 M 1 1 1 Wild type Sensitive
4 83 Md 3 2 1 Wild type Not available
5 30 M 1 1 1 Wild type Sensitive
6 42 Fd 4 3 3 Wild type Sensitive
7 30 Md 1 1 1 Wild type Not available
8 56 Md 2 1 1 Wild type Sensitive
9 80 F 2 2 1 Wild type Not available
10 31 F 3 2 1 Wild type Sensitive
11 40 Md 1 1 1 Wild type Sensitive
12 65 M 1 1 1 Wild type Sensitive
13 40 F 2 1 Sensitive
14 40 Md 2 1 Sensitive
15 31 Md 1 1 Sensitive
16 34 Md 1 1 1 Abnormal Resistant
17 35 Md 1 1 1 Abnormal Resistant
18 30 Md 4 3 1 Abnormal Resistant
19 26 Md 3 3 3 Abnormal Resistant
Confirmed to have CNS-TB at autopsy
20 30 M 1 1 1 Abnormal Resistante
21 33 Md 4 4 4 Abnormal Resistante
22 36 Md 2 2 2 Abnormal Resistante
Highly probable cases
23 51 F 2 1 1 Wild type Not available
24 27 Fd 2 2 1 Wild type Not available
25 29 Md 2 1 1 Wild type Not available
26 30 Md 1 1 1 Wild type Not available
27 29 M 1 1 Not available
28 30 Fd 2 2 2 Abnormal Resistante
29 41 F 7 3 4 Wild type and
Abnormalf
Not available
Total no. of samples
(no. of patients)
65 (29) 49 (29) 37 (25)
a M, male; F, female.
b SSCP patterns were classified as wild type or abnormal in the case of single DNA strands with electrophoretic mobilities identical to or different from that of a
reference strain (M. tuberculosis H37rv [ATCC 27294]), respectively.
c See Materials and Methods for more information on classification criteria.
d Patients coinfected with HIV.
e Susceptibility testing determined with isolates cultured from respiratory specimens.
f SSCP analysis showed a wild type in the baseline and an abnormal pattern in three subsequent CSF samples.
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each nucleotide substitution a specific and characteristic SSCP
pattern was observed (Fig. 1). No mutations were revealed in
the rpoB segment sequenced from the rifampin-sensitive ref-
erence strain (ATCC 27294).
Seventeen M. tuberculosis strains (nine rifampin-sensitive
and eight rifampin-resistant strains) cultured from samples
collected from patients with CNS-TB were available for direct
DNA sequencing. No mutations were revealed in the rpoB
segment sequenced from the rifampin-sensitive strains, whereas
single point mutations were detected in all of the strains with a
resistant phenotype. Three different kinds of nucleotide sub-
stitution were revealed in two codons of the rpoB gene, which
were specific and characteristic for each SSCP pattern (Fig. 2).
The mutations were located in codon 531, reading TTG in-
stead of TCG (Ser3Leu), and in codon 526, reading GAC and
TAC instead of CAC (His3Asp and His3Tyr). These three
single-base substitutions represent 56 to 68% of the mutations
associated with rifampin resistance detected worldwide (4, 12,
20, 23).
The 17 M. tuberculosis strains were also analyzed by means
of RFLP analysis with IS6110 as a hybridization probe. The
number of IS6110 copies in these strains varied from 1 to 14,
and a total of nine and four RFLP patterns were identified for
susceptible and resistant strains, respectively. Patients 17 to 22
suffered from disseminated tuberculosis sustained by two dis-
tinct multidrug-resistant isolates that caused two nosocomial
outbreak in four infectious diseases divisions in northern Italy
(data not shown).
DISCUSSION
The presence of mutations in a restricted sequence of the
rpoB gene has been found in more than 96% of M. tuberculosis
strains with various levels of Rifr (4, 7, 10, 12, 19, 20, 22, 23);
the degree of resistance, determined by measuring the MICs,
seems to be related to the type of mutation (2). The use of
molecular biology-based techniques in the search for Rifr at
the genomic level is more rapid (and therefore of greater help
in therapeutic decision making) than the use of conventional
methods based on verifying the growth of the organism in
antibiotic-containing culture media.
Various investigators have reported encouraging results
concerning the validity of this new approach when the DNA is
extracted from mycobacterial cultures (4, 7, 10, 12, 19, 20, 22,
23), but the detection of mutations in DNA extracted directly
from pathological clinical samples (which would save an even
greater amount of time) is still hampered by unresolved meth-
odological problems mainly due to the poor sensitivity and
specificity of the adopted amplification protocols (10, 23). Be-
cause only a single copy of the rpoB gene is present in myco-
bacterial DNA, PCR protocols with this target are less sensi-
tive than those amplifying repeated sequences, such as IS6110.
Furthermore, given that the rpoB gene is highly conserved in
the various GC-rich bacterial species colonizing the respiratory
tract, it is possible that the generation of nonspecific amplifi-
cation products may interfere with subsequent analysis (10). It
is for this reason that, at least in the early studies, the detection
of Rifr at the genomic level by means of SSCP, heteroduplex
formation, and DNA sequencing analyses of PCR products
was only possible with samples with a high mycobacterial load
that could be revealed by microscopy (10, 11). Whelen et al.
(22) have recently optimized a single-tube heminested PCR
protocol and obtained rpoB gene amplification products for
87.5% of various types of culture-positive samples, some of
which were negative by microscopic examination. Neverthe-
less, the use of highly sensitive double amplification protocols
not only increases the risk of contamination but could theo-
retically lead to the generation of amplification products from
only a few DNA targets, which means that there is a risk that
the subsequent analysis of the amplified DNA may not reflect
the real percentage of mutated organisms among the bacterial
population in the pathological sample.
The present paper reports the results of the SSCP and DNA
sequencing analyses of rpoB gene amplification products ob-
tained by processing CSF samples and M. tuberculosis strains
from subjects with CNS-TB. Amplification products suitable
for the subsequent detection of mutations were obtained from
the CSF samples drawn from 16 (84.2%) of the 19 subjects
whose CNS-TB was confirmed by means of cultural investiga-
tions and from 9 (90%) of the 10 subjects whose CSF cultures
were negative but whose disease was confirmed at autopsy or
considered highly probable. Overall, SSCP analysis proved to
be possible for 86.2% of the patients. This result was achieved
thanks to the use of the mycobacterial DNA concentration,
extraction, and purification process applied to large volumes of
CSF and the use of a highly specific enzyme that can be acti-
vated at high temperatures, which made it possible to increase
the number of amplification cycles (1). The sensitivity of this
method was similar to that of a nested PCR protocol based on
the final synthesis of the same sequence and use of the outer
primers described by Kapur et al. (12) (data not shown).
In our experience, the detection of rifampin susceptibility by
means of the genotypic study of the mycobacterial DNA
present in pathological samples, using SSCP analysis as an
indirect method of revealing the presence of mutations, has
proved to be an approach that is highly predictive of the
strain’s phenotype determined by conventional susceptibility
testing. All of the M. tuberculosis strains cultured from the CSF
or respiratory samples obtained from 17 patients with CNS-TB
showed a rifampin phenotype that was in line with the results
of the SSCP analysis. For eight patients, it was not possible to
compare the rifampin phenotype with the SSCP data because
no susceptibility testing results were available. The clinical and
radiological documentation concerning these patients was crit-
ically reviewed with the aim of evaluating the evolution of the
disease after the initiation of specific treatment with isoniazid,
rifampin, ethambutol, and pyrazinamide. No evaluation was
FIG. 2. PCR-SSCP patterns obtained by processing CSF samples from pa-
tients with CNS-TB. Lanes S, pattern obtained from rifampin-sensitive M. tu-
berculosis reference strain (ATCC 27294). Samples (lanes) 1 to 3, patterns
obtained from specimens collected from patients with CNS-TB caused by ri-
fampin-resistant strains. These patterns were expressions of single base substi-
tutions in codon 526 of the M. tuberculosis rpoB gene, reading GAC instead of
CAC (His3Asp); in codon 531, reading TTG instead of TCG (Ser3Leu); and
in codon 526, reading TAC instead of CAC (His3Tyr), respectively. Samples
(lanes) 4 to 7, patterns obtained from specimens drawn from a patient (patient
29; see Table 1) before and during antituberculosis treatment; note the change
from a wild-type pattern (sample 4) to an abnormal one (samples 5 to 7), which
may have been an expression of selection of a clone carrying a mutation which
causes a Rifr phenotype. This finding correlates well with the clinical and neu-
roradiological evolution of the disease in this patient.
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possible for three patients (patients 7, 23, and 24), because
they died within a week of the onset of the disease, whereas a
complete cure was obtained for four patients (patients 4, 9, 25,
and 26) (data not shown). SSCP analysis did not reveal any
rpoB gene mutations in the genomes of the mycobacterial
isolates from the CSF of these patients. Analysis of the ampli-
fied products obtained by processing four samples drawn from
patient 29 before and during antibiotic treatment revealed a
change from a wild-type to an altered SSCP pattern, which may
have been an expression of a mutation which causes a Rifr
phenotype. This finding correlates well with the clinical and
neurological evolution of the disease in this subject: The first 6
months of treatment led to an encouraging improvement, as
demonstrated by the partial regression of some encephalitic
foci, but the disease gradually worsened again until the onset
of hydrocephalus and the need for drainage.
In conclusion, SSCP analysis of rpoB gene amplification
products obtained from mycobacterial DNA taken from the
CSF of subjects with CNS-TB appears to be a promising
method for determining mutations that confer resistance to
rifampin. Its use can radically reduce the time needed to pro-
vide clinicians with data that are useful in aiding the selection
of active drugs for the efficacious treatment of tuberculosis.
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